Juan David Flórez-Arango

Medical Oncologist: Lung Cancer, Thymic Cancer, Head and Neck Cancer & Thyroid Cancer. Medellín - Colombia

[Juan David Flórez-Arango @juandfar]

#ThymicTumors do not have a standard treatmentafter progression to platinum.#Everolimus may be an option, but we need to be able to identify molecular predictors of response to improve patient selection.Let's discuss more in the #MAP2022 poster session.@BenjaminBesseMD @OncoAlert

[La Silla Vacía @lasillavacia]

#Investigación

Junio de 2024. El presidente @petrogustavo es captado en Panamá de la mano de una mujer hasta ahora desconocida.

Su nombre es Vanessa Cortés y desde que Petro es presidente, ha tenido un rápido crecimiento patrimonial.

Va 🧵

[Ben Creelan, MD MS @BenCreelan]

High quality study from @BenjaminBesseMD showing only 26% of pts need retreatment after getting 2 yrs pembro for NSCLC.

However, outcome for IO rechallenge was mixed, w/ many pts clearly not responding and dying. Much like CM-153 & w/ prior pooled report of Abreu-Rodriguez showing only 19-27% ORR with pembro re-challenge.

So still an unresolved question: whether 2-yr discontinuation is optimal for all patients?

@GustaveRoussy

[Diego A. Díaz-García @diegoadiazg]

🫁 CheckMate 743: 5-Year Survival Update.

In unresectable pleural mesothelioma, first-line nivolumab plus ipilimumab maintains OS benefit vs chemotherapy at 66.8 months.

5-year OS: 14% vs 6%, HR 0.74 (95% CI 0.62–0.88)
Adjusted for 24% crossover: HR 0.64 (95% CI 0.53–0.78).
High baseline M-MDSCs associated with worse OS (HR 1.25). No new safety signals.

📖 @JCO_ASCO
DOI 👉🏻 https://t.co/8NdsbELlvA

#CánCare #Mesothelioma #Immunotherapy #ICI #ThoracicOncology

[Patrick Forde @FordePatrick]

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial | Nature Communications https://t.co/aBRBVKLvrX

[d.planchard @dplanchard]

Great review @JTOonline on the latest breakthroughs for non-V600E BRAF NSCLC patients, led by @SandraOrtizCua1 within our #BOLEROconsorti. Join our efforts to advance lung BRAF research! 🚀 #Oncology
#BRAF #lungcancer

[Iván Cepeda Castro @IvanCepedaCast]

Nicolás Maduro es digno sucesor de Hugo Chávez y trabajará también por la Paz en Colombia.

[d.planchard @dplanchard]

Trastuzumab Deruxtecan monotherapy benefit (cORR:44.4% and mPFS: 8.2mo) confirmed in pretreated HER2-overexpression (IHC 3/2+) NSCLC pts (Results Part 1 of Phase 1b DESTINY- Lung03 Trial) @JTOonline

[Diego A. Díaz-García @diegoadiazg]

🫁 1L immunotherapy vs targeted therapy in BRAFV600E-mut NSCLC (FRONT-BRAF).

In BRAFV600E-mutated metastatic NSCLC, first-line immunotherapy (± chemo) improved OS vs BRAF+MEK inhibitors (40.9 vs 25.2 mo). Benefit was greater in PD-L1 ≥1%, TP53 co-mut, smokers, and ≥70y.

📖 @TheLancetOncol
DOI 👉🏻 10.1016/S1470-2045(25)00409-7

#CánCare #NSCLC #lungcancer #immunotherapy #BRAF #MEK #ICI #oncology

[Pablo Jiménez @PaulJiL]

🚨Update in Head&Neck SCC @NCCN Evidence Blocks

💉neoadjuvant #pembrolizumab added!
Highlighting indication for resectable stage III/IVa CPS+, excluding N3
💉Sc R/M #nivolumab (review new doses 600mgQ2W/1200mgQ4W)

👇v5 Pics @OncoAlert @brunolarvol @BAHNOOfficial @ttccgroup

[EGFR Resisters @EGFRResisters]

https://t.co/ES8QbPrsur

[Tuğba Başoğlu, MD @tugbawitter]

🚨 NSCLC & ICI Resistance
Mutations inKEAP1,SMARCA4 & PTEN reshape TME → driving poor responses to ICIs
📉 Even wth high PD-L1/TMB, outcomes remain dismal.
⚠️ The triple-mutant group (KRAS+KEAP1+STK11) shows the worst resistnce & prognosis
https://t.co/3GTOXHEMCT

[Lung Cancer Europe @LungCancerEu]

🚨 #Lungcancer survival has more than doubled.

New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment.

This is what progress looks like. But it must reach everyone who needs it.

🔗 @NEJMEvidence June 2025
https://t.co/dKMo9xApKK

#LCSM

[Yüksel Ürün @DrYukselUrun]

BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112

[Benjamin Besse @BenjaminBesseMD]

YES! De-escalation trials matter and should be much more supported by payers! Very preliminary results from the Dutch non inferiority trial DEDICATION-1 are reassuring. In France, the PULSE trial has the same hypothesis, opens soon in Belgium, Spain, Estonia and Greece! #ESMO24

[Annals of Oncology @Annals_Oncology]

New article in press: Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase 3 trial.
https://t.co/ZUDx6Bippd

[ESMO - Eur. Oncology @myESMO]

📣 The new ESMO Living Guideline on Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer is now online.

🔗 https://t.co/63o3YSaRXk

[Benjamin Besse @BenjaminBesseMD]

Stop pembro after 2 years?

In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95.
@arousseaumd

https://t.co/It7wr78ilx

[Tom Newsom-Davis @tnewsomdavis]

Chemotherapy for thymoma

👉 Anthracycline containing vs. non-anthracycline regimens

❗️Anthracycline regimens have higher ORR, but no difference in PFS or OS

🔹 Big retrospective study
🔹 No AE data

🤔 Reassures that either approach is reasonable

Abstract 8111
#ASCO24 #LCSM

[NEJM @NEJM]

Presented at #ASCO24:

Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: https://t.co/ZxWxo2qgNy

[Stephen V Liu, MD @StephenVLiu]

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM

https://t.co/pKqUJu55Tk